wolfstreetswinger

OPHT - Strong buy on intriguing news

做多
wolfstreetswinger 已更新   
NASDAQ:OPHT   None
I recommend to buy a dip or breakup here. I like OPHT for its wild swings on news some might see this as risk but staying in the loop should see us fine and its shares are up considerably on its latest update being that it is set to report registration-ready late-stage trial results for its vision-restoring drug Fovista, which coupled with other drugs already on the market would make a great improvement and it appears that the outcome of those trials will be very good.

I wont go in to great detail as with any investment i recommend to do your own research and analysis before taking any trade but i will update with trial results and fda approvals .

Also to note many analysts are expecting prices to soar back into $90+ region.

Good luck.
评论:
TRIALS FAILED STAGE 3
订单已取消

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。